Vestal Point Capital »

Denali Therapeutics shares owned by Vestal Point Capital

Quarter-by-quarter ownership of Denali Therapeutics (DNLI) shares owned by Vestal Point Capital from 13F filings

Historical chart of Vestal Point Capital investment in Denali Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Denali Therapeutics held by Vestal Point Capital consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Denali Therapeutics by Vestal Point Capital

Quarter filed Position value Share count Share price at filing
2024-06-30 $12M 500k 23.22

More positions owned by Vestal Point Capital

Jazz Pharmaceuticals Shs Usd (JAZZ)
Cytokinetics Com New (CYTK)
Ascendis Pharma A/S Sponsored Adr (ASND)
Ultragenyx Pharmaceutical (RARE)
Globus Medical Cl A (GMED)
Insmed Com Par $.01 (INSM)
BeiGene Sponsored Adr (BGNE)
Soleno Therapeutics (SLNO)
EXACT Sciences Corporation (EXAS)
Arcellx Common Stock (ACLX)
Immatics NV SHS (IMTX)
Janux Therapeutics (JANX)
Astria Therapeutics (ATXS)
Kalvista Pharmaceuticals (KALV)
Savara (SVRA)

View all positions for Vestal Point Capital

Top funds holding Denali Therapeutics

Baillie Gifford & Co
BlackRock
Vanguard Group
Wellington Management Company
Capital Research Global Investors
Temasek Holdings
Crestline Management
State Street Corporation
Baker Bros. Advisors
Geode Capital Management
Marshall Wace
T. Rowe Price Associates
Alliancebernstein
Credit Suisse
Bank of New York Mellon

View all funds holding Denali Therapeutics